2025-05-14 - Analysis Report
Okay, here's a report analyzing Eli Lilly and Co (LLY) based on the provided data.

**Eli Lilly and Co (LLY) Analysis**

Eli Lilly and Co is a pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products worldwide.

**1. Performance vs. S&P 500 (VOO)**

*   **LLY Cumulative Return:** 245.11%
*   **VOO Cumulative Return:** 81.82%
*   **Absolute Divergence:** 163.3
*   **Relative Divergence:** 56.1 (meaning the current divergence is in the 56.1 percentile of its historical range)

**Analysis:** LLY has significantly outperformed the S&P 500. The relative divergence suggests that while LLY is performing well above the benchmark, there is still room for further outperformance based on historical data.

**Alpha, Beta Analysis**

| Year        | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
|-------------|---------|---------|---------|--------|--------|
| 2015-2017   | 10.0%   | 55.6%   | -19.0%  | 0.1    | 67.7   |
| 2016-2018   | 38.0%   | 58.6%   | 20.0%   | -0.1   | 95.0   |
| 2017-2019   | 49.0%   | 58.6%   | 19.0%   | 0.3    | 110.4  |
| 2018-2020   | 51.0%   | 58.6%   | 25.0%   | 0.2    | 144.7  |
| 2019-2021   | 105.0%  | 60.7%   | 50.0%   | 0.3    | 240.3  |
| 2020-2022   | 100.0%  | 65.0%   | 94.0%   | 0.3    | 322.6  |
| 2021-2023   | 138.0%  | 65.0%   | 122.0%  | 0.3    | 519.0  |
| 2022-2024   | 156.0%  | 72.1%   | 139.0%  | 0.3    | 691.9  |
| 2023-2025   | 95.0%   | 76.9%   | 66.0%   | 0.2    | 669.8  |

**Analysis:** The table shows a strong CAGR and increasing market capitalization over the years.  The consistently positive Alpha indicates that LLY has been generating returns above what would be expected based on market movements alone. The Beta values are relatively low, suggesting LLY's price is not as volatile as the market. The Maximum Drawdown (MDD) also indicates a moderate level of risk.

**2. Recent Price Action**

*   **Current Price:** 746.06
*   **Previous Close:** 755.57
*   **Change:** -1.26%
*   **5-day Moving Average:** 752.87
*   **20-day Moving Average:** 809.57
*   **60-day Moving Average:** 826.18

**Analysis:** LLY's recent price has declined. The current price is below the 5-day, 20-day, and 60-day moving averages, which may indicate a short-term downtrend. The negative change from the previous close supports this observation, and the recent drop suggests a degree of selling pressure.

**3. Market Risk Indicators**

*   **Market Risk Indicator (MRI):** 0.348 (Low Risk)
*   **RSI:** 37.78 (Approaching Oversold)
*   **PPO:** -1.30
*   **20-day Relative Divergence Change:** -3.9 (Short-term decline)
*   **Expected Return:** 120.1% (Long-term, relative to S&P 500)

**Analysis:** The MRI suggests a low-risk environment.  The RSI value indicates that the stock is approaching oversold conditions, potentially signaling a buying opportunity. The negative PPO indicates a downtrend. The negative change in relative divergence supports the short-term decline. The high expected return suggests a potentially strong long-term investment opportunity. The price change from the previous close indicates a negative issue

**4. Recent News & Significant Events**

*   **May 13, 2025:** Eli Lilly and Co (LLY) has recently made headlines due to major business developments, regulatory changes, or market events.
*   **May 10, 2025:** Analysts are discussing Eli Lilly and Co's (LLY) recent performance and its outlook in the context of industry trends and global economic factors.
*   **May 12, 2025:** Eli Lilly and Co (LLY)'s stock has shown notable volatility, influenced by recent news, earnings reports, or executive actions.
*   **May 14, 2025:** Market experts highlight both risks and opportunities for Eli Lilly and Co (LLY), advising investors to monitor recent news and company announcements.

**Analysis:** Recent news suggests that LLY is experiencing significant activity and attention from analysts and the market. This could be related to positive earnings, regulatory changes, or market events. Investors should carefully monitor company announcements and news related to LLY to understand the underlying factors driving the stock's volatility.

**5. Recent Earnings Analysis**

| 날짜        | EPS  | 매출      |
|-------------|------|-----------|
| 2025-05-01  | 3.07 | 12.73 B$  |
| 2024-10-30  | 1.08 | 11.44 B$  |
| 2024-08-08  | 3.29 | 11.30 B$  |
| 2024-04-30  | 2.49 | 8.77 B$   |
| 2025-05-01  | 2.49 | 8.77 B$   |

**Analysis:** Revenue has generally increased, and recent EPS figures have been strong. Revenue and EPS figures suggest a healthy performance and indicate positive growth. The recent earnings data is an encouraging sign.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-03-31   | $12.73B   | 82.53%        |
| 2024-12-31   | $13.53B   | 82.24%        |
| 2024-09-30   | $11.44B   | 81.02%        |
| 2024-06-30   | $11.30B   | 80.80%        |
| 2024-03-31   | $8.77B    | 80.91%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE      |
|--------------|------------|----------|
| 2025-03-31   | $15.76B   | 17.50%   |
| 2024-12-31   | $14.19B   | 31.07%   |
| 2024-09-30   | $14.24B   | 6.81%    |
| 2024-06-30   | $13.56B   | 21.88%   |
| 2024-03-31   | $12.81B   | 17.51%   |

**Analysis:** Revenue has generally increased, and profit margins remain high.  The Return on Equity (ROE) has fluctuated, but generally indicates good profitability. The increasing equity suggests good financial health.

**7. Overall Summary**

Eli Lilly and Co (LLY) has demonstrated strong historical outperformance compared to the S&P 500, reflected in its high cumulative returns and positive alpha. Recent price action indicates a short-term downtrend, potentially driven by recent news events and market volatility. However, the company exhibits a low-risk profile, as indicated by the Market Risk Indicator (MRI). The recent earnings analysis and financial data show strong revenue growth, high-profit margins, and healthy equity levels, suggesting sound financial health. The high expected return suggests a strong long-term investment opportunity.

**In summary:** LLY shows significant potential for long-term growth, but investors should be aware of recent short-term price volatility and monitor news events and company announcements closely. The data suggests a possible buying opportunity given the oversold RSI and potential long-term upside.
